MILESTONES
A decade of building the foundation
From the founding priority filing to a globally protected estate and an independently validated body of evidence.
2026
A globally protected estate
45 active patent assets, 36 granted or validated, across 11 national jurisdictions plus European Patent coverage.
2025
A new therapeutic class defined
Deaminase modulation defined as an emerging drug class in the peer-reviewed literature (Lindley, IJMS).
2024–25
Multi-centre IO-response validation
Independent validation across NSCLC and melanoma cohorts with leading centres, plus mechanistic validation with the Hudson Institute.
2021
Recurrence signatures at scale
Deaminase-associated recurrence signatures characterised across 10,000+ TCGA samples (Mamrot, Oncotarget).
2020
Progression prediction
Progression-prediction and prognostic risk-stratification methods filed (Family 4).
2017
Therapy-efficacy prediction
Cancer-Progression Associated Signatures (C-PAS) methods filed (Family 3).
2016
First clinical validation
Codon-context signatures validated in high-grade serous ovarian cancer: 95% sensitivity, 90% specificity (Lindley, Cancer Medicine).
2015
Recurrence detection
Recurrence-monitoring methods filed (Family 2).
2012
Foundation priority
First Targeted Somatic Mutation methods filed, establishing the foundational Family 1 priority position.